DOCSLIB.ORG

Research on Smoking Behavior, 17

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Research on Smoking Behavior, 17 U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Research on Smoking Behavior Editors: Murray E. Jarvik, M.D., Ph.D. Joseph W. Cullen, Ph.D. Ellen R. Gritz, Ph.D. Thomas M. Vogt, M.D., M.P.H. Louis Jolyon West, M.D. NIDA Research Monograph 17 December 1977 DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 Stock Number 017-024-00694-7 The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical re views of research problem areas and techniques, the content of state-of-the-art conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Palo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco California William McGlothlin, Ph.D. Department of Psychology. UCLA Los Angeles, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Office of Drug Education. DHEW Washington, D.C. Lee Robins, Ph.D. Washington University School of Medicine St. Louis. Missouri NIDA Research Monograph series Robert DuPont, M.D. DIRECTOR, NIDA William Pollin, M.D. DIRECTOR, DIVISION OF RESEARCH, NIDA Robert C. Petersen, Ph.D. EDITOR-IN-CHIEF Eunice L. Corfman, MA. EDITOR Eleanor W. Waldrop MANAGING EDITOR Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857 Research on Smoking Behavior ACKNOWLEDGEMENT This monograph is derived from papers presented at a conference on smoking behavior convened at the University of California at Los Angeles, June 24 and 25, 1977. (An indication of their impact is that the editor of the NIDA Research Monograph series has stopped smoking .) Ms. Toby-Ann Cronin played a critical role in the coordination of the conference and in the development of this publication, under NINA contract #271-77-3422 with UCLA. Library of Congress catalog number 77-090890 DHEW Publication No. (ADM) 78-581 Printed 1978 NIDA Research Monographs are indexed in the Index Medicus. They are selectively included in the coverage of Biosciences Information Service, Chemical Abstracts, Psychological Abstracts, and Psychopharmacalogy Abstracts. iv Foreword In the 14 years since the 1964 Advisory Committee’s Report to the Surgeon General on smoking, awareness of the important effect of this widespread behavior on the nation’s health has moved in op- posite and paradoxical directions. On the one hand, the Report triggered significant changes. A distinct drop in cigarette con- sumption occurred in that year, and since then consumption has de- creased for adult males from 52 per cent to 39 per cent and for adult females from 32 per cent to 29 per cent. A 1975 study shows the number of physicians still smoking has decreased from 30 per cent in 1967 to 21 per cent, dentists from 34 per cent to 23 per cent, and pharmacists from 35 per cent to 28 per cent. On the other hand, the knowledge has become trite and the magnitude of the dam- age lost sight of. Fifty million Americans still smoke. Ominously, smoking by girls between 12 and 18 nearly doubled between 1968 and 1974, eliminating the difference in smoking behavior between the two sexes. The age at which many children begin regular smoking is down to 11 to 12 years. Not only is early onset of a drug habit often predictive of heaviness of use and difficulty of cessation, but cigarette smoking is often a precursor or gateway substance to use of stronger drugs. Most people, including health officials, are startled when the fig- ures on smoking damage are put into perspective. For example, the number of people who annually die prematurely from smoking is es- timated at 300,000. For comparison, annual automobile fatalities are estimated at about 55,000, overdose deaths attributed to bar- biturates are estimated at about 1,400, and to heroin at about 1,750. Over 37 million people (one of every six Americans alive today) will die from cigarette smoking years before they otherwise would. If tobacco-related deaths were eliminated, there would be: 300,000 Americans each year who would not die prematurely 1/3 fewer male deaths from 35 to 59 85 per cent fewer deaths from bronchitis or emphysema 1/3 fewer deaths from arteriosclerosis 1/3 fewer deaths from heart disease 90 per cent fewer deaths from cancer of the trachea and lungs 50 per cent fewer deaths from cancer of the bladder Given the extent of the problem, a consensus is growing that the national effort to cope with it has been defective. Not qualita- tively, since good people have done substantial and important work, and many lives have been saved. But quantitatively the effort has v been too little and its priority insufficiently urgent. Cigarette smoking is the largest preventable cause of premature death, ill- ness, and disability we have. These smoking damage figures are so large because of heavy promotion, governmental protection and sub- sidy,. a health industry largely preoccupied with other things, and an entrenched and overlearned addictive behavior that has proven extraordinarily hard to reduce or extinguish, But what should we think of ourselves, individually or collectively as a nation, if we concede, therefore, that we are helpless to change this toll and must learn to tolerate it? The NIDA Division of Research has given increased priority to this issue during the past few years for several reasons: the increasing identification of smoking as a prototypic addiction, the status of smoking as a gateway drug to use of stronger or illicit drugs, and our focus on substance abuse as a generic phenomenon that includes tobacco. The Royal College of Physicians 1977 report on Smoking and Health says of the habit, " . tobacco smoking is a form of drug dependence different from but no less strong than that on other drugs of addiction.. " The current International Classification of Diseases (ICD) now lists tobacco smoking disorder as a drug prob- lem, and, as Dr. Jerome Jaffe tellingly recounts in this monograph, so, at last, does the new psychiatric Diagnostic and Statistical Manual (DsM)III draft revision. Public health policy on smoking should probably recognize that ex- tinction of the habit is an unrealistic goal and even undesirable, given the adjunctive coercion such a goal would require. But we should take care to devote a degree of concern and excellence to understanding and dealing with the problem that is’ commensurate with its size. The idea of control appears central, whether this is ex- ercised in brain and CNS responses, by genetic or psychological pre- disposition, through learning or reinforcing factors in the cultural and institutional environment. Cur research agenda needs to address all these levels. Correspondingly, one measure of the usefulness of the papers in this monograph is their scope, from the basic opponent process theory formulated by Dr. Joseph Ternes to the activist prevention policy presented by Dr. Ellen Gritz; from the differently impressive syn- optic views of Drs. Russell and Van Lancker to the valuable particu- lar cost figures calculated by Drs. Lute and Schweitzer. To have put between two covers a set of papers of such high caliber, time- liness, and utility is a welcome achievement. William Pollin, M.D. Director Division of Research National Institute on Drug Abuse vi Preface The National Institute on Drug Abuse has been given the lead role in the Federal Government to carry out and support research on tobacco smoking behavior. Unlike other Federal efforts in this area of public health, NIDA will focus its effort on the dependence pro- cess associated with tobacco smoking. Tobacco smoking can be viewed as a prototype dependence ‘process which has a significant impact on the public health. The morbidity and premature mortality figures associated with this habitual behavior ark high. It is estimated, for example, that some 250,000-300,000 premature deaths can be di- rectly or indirectly related to tobacco smoking. While much re- search has been devoted to the biomedical and pathological conse- quences of smoking (early onset of cardiovascular and pulmonary di- sease and lung cancer), relatively little Federal research support has been provided for understanding the biological, behavioral, psychological, and societal factors which may be substantial in the etiology and maintenance of this habitual behavior. Little, if any, research has been focused on elucidating withdrawal phenomena associated with cessation of smoking or factors leading to relapse and recidivism. Other areas of research which are ripe for develop- ment are innovative treatment procedures for teaching people how to stop smoking and pharmaco-therapeutic techniques for maintaining abstinence. Development of biological assays to detect tobacco, nicotine, and its metabolites is essential. Such technology would afford researchers a way to validate self report data in follow-up studies and epidemiological surveys of smokers. NIDA is currently developing an extra-mural funding program targeted for research on tobacco smoking as a dependence process. Part of our effort in this area of smoking research is exemplified by this conference. Norman A. Krasnegor, Ph.D. Division of Research National Institute on Drug Abuse vii Monograph Contributors Ransom J. Arthur, M.D. Jerome H. Jaffe, M.D.
Load more

Recommended publications
  • Richard Doll
    2825 Obituary: Richard Doll Sir Richard Doll died earlier this year at age 92. The most The studies by Doll are bold and original science. They celebrated epidemiologist of the 20th century, Doll is best represent an important part of the foundation of modern known for his work on smoking and lung cancer, but there was population-based chronic disease research. By the early 1960s, so much more to his career. they constituted adequate evidence for public health action to His father was a general practitioner in London, and it was reduce tobacco smoking; in 1964, the U.S. Surgeon General’s from St. Thomas’s that Doll himself graduated in Medicine in first report on the adverse health consequences of tobacco was 1937. Even as a student, he showed his interest in epidemi- published. Today, they continue to remind us how carefully ologic and statistical tools, publishing on the need for proper crafted observational studies can advance scientific knowledge analysis and statistical testing in population studies of disease. regarding social and health issues that are not amenable to Later, Doll served in the Royal Medical Corps in France and experimentation on human populations. the Middle East throughout the Second World War. He began Asbestos. By the early 1930s, work in the asbestos products his research career at the Middlesex Hospital, studying industry in Britain was known to increase the risk of a occupational factors in the development of peptic ulceration. sometimes fatal nonmalignant pulmonary disease, termed He married Dr. Joan Faulkner around this time, and it was she asbestosis.
    [Show full text]
  • Date of Preparation October 1, 2020 Format of This CV: Committee On
    Date of Preparation October 1, 2020 Format of this CV: Committee on Appointments and Promotions Mailman School of Public Health, Columbia University Personal data Steven D. Stellman Birthdate: May 7, 1945 Birthplace: Toronto, Canada Citizenship: USA Academic appointments 1966-71 Teaching Fellow, Department of Chemistry, New York University 1971-73 Research Associate, Division of Biochemical Sciences, Princeton University 1973-74 Lecturer in Chemistry, University of Colorado, Denver 1978-82 Adjunct Associate Professor, Hunter College of the City University of New York, Depts. of Chemistry and Environmental Health Sciences 1979-82 Adjunct Associate Professor, Dept. of Research Medicine, University of Pennsylvania School of Medicine 1980-81 Adjunct Associate Professor, Dept. of Epidemiology, Cornell University School of Medicine 1981-94 Adjunct Associate Professor, Dept. of Community Medicine, Mt. Sinai School of Medicine, New York, NY 2000 - Professor of Clinical Epidemiology, Mailman School of Public Health, Columbia University; Assoc Chair, 2016- Education Ohio State University, B.Sc. 09/1964 to 06/1966, Chemistry. New York University, Ph.D. 09/1966 to 1971, Physical chemistry. Thesis title: Computer simulation of polymer conformation and conformational thermodynamics. Sponsor: Paul J. Gans, Ph.D. Citations: (1) Stellman SD, Froimowitz M, Gans PJ. J Computational Physics 1971; 7:179-182. (2) Stellman SD, Gans PJ. Macromolecules 1972; 5:516-526. (3) Stellman SD, Gans PJ. Macromolecules 1972; 5:720-729. Columbia University, M.P.H., 09/1990 to 06/1992, Executive MPH Program in Health Policy & Management Traineeships 1968-71 New York University, National Science Foundation Graduate Traineeship 1971-73 Princeton University, Post-doctoral fellow, Dept. of Biochemical Sciences Professional organizations and societies Society for Epidemiologic Research American College of Epidemiology American Public Health Association American Chemical Society American Society of Preventive Oncology Steven D.
    [Show full text]
  • ASH NEW ZEALAND Tobacco Returns Analysis 2013 1 TOBACCO
    ASH NEW ZEALAND Tobacco Returns Analysis 2013 TOBACCO RETURNS ANALYSIS 2013 Tobacco manufacturers and importers in New Zealand are required to file their annual tobacco returns pursuant to section 35 of the Smokefree Environments Act 1990. The tobacco returns consist of two components – Schedule A and Schedule B. Schedule A is the information about ingredients and amounts used in their tobacco products. Schedule B is the company list of all their products, retail price and sale quantity We analysed data from Schedule B in order to understand the brand positioning of the major tobacco companies. This includes analysis of retail price, sale volume and estimated sales returned of all tobacco brands. Market share also is estimated based on this data. This analysis accounted for cigarette and loose leaf tobacco products sold within New Zealand (or domestic market). Information provided by tobacco companies may vary and hence the results of the analysis. British American Tobacco New Zealand (BATNZ) provided recommended retail prices as at January 2013 while Imperial Tobacco New Zealand and Philip Morris provided theirs as at December 2013. This had resulted in artificially higher estimates of average retail price and sale return for BATNZ products due to the January 2014 tax increase. Having considered this, most of the results on overall tobacco market in this analysis were presented according to the sale quantity and hence better accuracy. Fourteen companies filed their tobacco returns in 2013. As this analysis only included cigarette and loose leaf tobacco products, three companies were excluded as they sold cigar or other tobacco products. Tobacco Returns 2012 can be accessed through the National Drug Policy New Zealand website (http://www.ndp.govt.nz/moh.nsf/indexcm/ndp-tobacco-returns-2012 ).
    [Show full text]
  • Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion and Pharmacokinetics
    TESI DOCTORAL HUMAN PHARMACOLOGY OF AYAHUASCA JORDI RIBA Barcelona, 2003 Director de la Tesi: DR. MANEL JOSEP BARBANOJ RODRÍGUEZ A la Núria, el Marc i l’Emma. No pasaremos en silencio una de las cosas que á nuestro modo de ver llamará la atención... toman un bejuco llamado Ayahuasca (bejuco de muerto ó almas) del cual hacen un lijero cocimiento...esta bebida es narcótica, como debe suponerse, i á pocos momentos empieza a producir los mas raros fenómenos...Yo, por mí, sé decir que cuando he tomado el Ayahuasca he sentido rodeos de cabeza, luego un viaje aéreo en el que recuerdo percibia las prespectivas mas deliciosas, grandes ciudades, elevadas torres, hermosos parques i otros objetos bellísimos; luego me figuraba abandonado en un bosque i acometido de algunas fieras, de las que me defendia; en seguida tenia sensación fuerte de sueño del cual recordaba con dolor i pesadez de cabeza, i algunas veces mal estar general. Manuel Villavicencio Geografía de la República del Ecuador (1858) Das, was den Indianer den “Aya-huasca-Trank” lieben macht, sind, abgesehen von den Traumgesichten, die auf sein persönliches Glück Bezug habenden Bilder, die sein inneres Auge während des narkotischen Zustandes schaut. Louis Lewin Phantastica (1927) Agraïments La present tesi doctoral constitueix la fase final d’una idea nascuda ara fa gairebé nou anys. El fet que aquest treball sobre la farmacologia humana de l’ayahuasca hagi estat una realitat es deu fonamentalment al suport constant del seu director, el Manel Barbanoj. Voldria expressar-li la meva gratitud pel seu recolzament entusiàstic d’aquest projecte, molt allunyat, per la natura del fàrmac objecte d’estudi, dels que fins al moment s’havien dut a terme a l’Àrea d’Investigació Farmacològica de l’Hospital de Sant Pau.
    [Show full text]
  • North Dakota Office of State Tax Commissioner Tobacco Directory List of Participating Manufacturers (Listing by Brand) As of May 24, 2019
    North Dakota Office of State Tax Commissioner Tobacco Directory List of Participating Manufacturers (Listing by Brand) As of May 24, 2019 **RYO: Roll-Your-Own Brand Name Manufacturer 1839 U.S. Flue-Cured Tobacco Growers, Inc. 1839 RYO U.S. Flue-Cured Tobacco Growers, Inc. 1st Class U.S. Flue-Cured Tobacco Growers, Inc. American Bison RYO Wind River Tobacco Company, LLC Amsterdam Shag RYO Peter Stokkebye Tobaksfabrik A/S Ashford RYO Von Eicken Group Bali Shag RYO Commonwealth Brands, Inc. Baron American Blend Farmer’s Tobacco Co of Cynthiana, Inc. Basic Philip Morris USA, Inc. Benson & Hedges Philip Morris USA, Inc. Black & Gold Sherman’s 1400 Broadway NYC, LLC Bo Browning RYO Top Tobacco, LP Bugler RYO Scandinavian Tobacco Group Lane Limited Bull Brand RYO Von Eicken Group Cambridge Philip Morris USA, Inc. Camel R.J. Reynolds Tobacco Company Camel Wides R.J. Reynolds Tobacco Company Canoe RYO Wind River Tobacco Company, LLC Capri R.J. Reynolds Tobacco Company Carlton R.J. Reynolds Tobacco Company CF Straight Virginia RYO Von Eicken Group Charles Fairmon RYO Von Eicken Group Chesterfield Philip Morris USA, Inc. Chunghwa Konci G & D Management Group (USA) Inc. Cigarettellos Sherman’s 1400 Broadway NYC, LLC Classic Sherman’s 1400 Broadway NYC, LLC Classic Canadian RYO Top Tobacco, LP Commander Philip Morris USA, Inc. Crowns Commonwealth Brands Inc. Custom Blends RYO Wind River Tobacco Company, LLC Brand Name Manufacturer Danish Export RYO Peter Stokkebye Tobaksfabrik A/S Dark Fired Shag RYO Von Eicken Group Dave’s Philip Morris USA, Inc. Davidoff Commonwealth Brands, Inc. Djarum P.T.
    [Show full text]
  • Cigarettes and Tobacco Products Removed from the California Tobacco Directory by Brand
    Cigarettes and Tobacco Products Removed From The California Tobacco Directory by Brand Brand Manufacturer Date Comments Removed #117 - RYO National Tobacco Company 10/21/2011 5/6/05 Man. Change from RBJ to National Tobacco Company 10/20's (ten-twenty's) M/s Dhanraj International 2/6/2012 2/2/05 Man. Name change from Dhanraj Imports, Inc. 10/20's (ten-twenty's) - RYO M/s Dhanraj International 2/6/2012 1st Choice R.J. Reynolds Tobacco Company 5/3/2010 Removed 5/2/08; Reinstated 7/11/08 32 Degrees General Tobacco 2/28/2010 4 Aces - RYO Top Tobacco, LP 11/12/2010 A Touch of Clove Sherman 1400 Broadway N.Y.C. Inc. 9/25/2009 AB Rimboche' - RYO Daughters & Ryan, Inc. 6/18/2010 Ace King Maker Marketing 5/21/2020 All American Value Philip Morris, USA 5/5/2006 All Star Liberty Brands, LLC 5/5/2006 Alpine Philip Morris, USA 8/14/2013 Removed 5/4/07; Reinstated 5/8/09 Always Save Liberty Brands, LLC 5/4/2007 American R.J. Reynolds Tobacco Company 5/6/2005 American Bison Wind River Tobacco Company, LLC 9/22/2015 American Blend Mac Baren Tobacco Company 5/4/2007 American Harvest Sandia Tobacco Manufacturers, Inc. 8/31/2016 American Harvest - RYO Truth & Liberty Manufacturing 8/2/2016 American Liberty Les Tabacs Spokan 5/12/2006 Amphora - RYO Top Tobacco, LP 11/18/2011 Andron's Passion VCT 5/4/2007 Andron's Passion VCT 5/4/2007 Arango Sportsman - RYO Daughters & Ryan, Inc. 6/18/2010 Arbo - RYO VCT 5/4/2007 Ashford Von Eicken Group 5/8/2009 Ashford - RYO Von Eicken Group 12/23/2011 Athey (Old Timer's) Daughters & Ryan, Inc.
    [Show full text]
  • Tobacco Dependency Needs Assessment
    Tobacco Dependence Needs Assessment January 2019 Produced by Claire Mulrenan, Public Health Registrar, Kent County Council Andrew Scott-Clark, Director of Public Health, Kent County Council Contents Executive Summary Background and Introduction ............................................................................................ 3 Epidemiology .................................................................................................................... 3 Smoking Cessation Services ............................................................................................... 4 1 Background ................................................................................ 6 2 Introduction ............................................................................... 6 Summary – Part 1 ................................................................................................................ 17 3 Epidemiology ............................................................................ 18 Summary – Part 2 ................................................................................................................ 31 4 Smoking Cessation Services ...................................................... 32 Summary and Recommendations – Part 3 ........................................................................... 41 Appendix 1 – Global Burden of disease ................................................................................ 43 Appendix 2- Cigarettes vs e-cigarettes ................................................................................
    [Show full text]
  • Hallucinogens: an Update
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Hallucinogens: An Update 146 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Hallucinogens: An Update Editors: Geraline C. Lin, Ph.D. National Institute on Drug Abuse Richard A. Glennon, Ph.D. Virginia Commonwealth University NIDA Research Monograph 146 1994 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGEMENT This monograph is based on the papers from a technical review on “Hallucinogens: An Update” held on July 13-14, 1992. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company.
    [Show full text]
  • Smoking Cessation Interventions in Pregnancy and Postpartum Care
    Evidence Report/Technology Assessment Number 214 Smoking Cessation Interventions in Pregnancy and Postpartum Care Evidence-Based Practice Evidence Report/Technology Assessment Number 214 Smoking Cessation Interventions in Pregnancy and Postpartum Care Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. 290-2007-10065-I Prepared by: Vanderbilt Evidence-based Practice Center Nashville, TN Investigators: Frances E. Likis, Dr.P.H., N.P., CNM Jeffrey C. Andrews, M.D. Christopher J. Fonnesbeck, Ph.D. Katherine E. Hartmann, M.D., Ph.D. Rebecca N. Jerome, M.L.I.S., M.P.H. Shannon A. Potter, M.L.I.S. Tanya S. Surawicz, M.P.H. Melissa L. McPheeters, Ph.D., M.P.H. AHRQ Publication No. 14-E001-EF February 2014 This report is based on research conducted by the Vanderbilt Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2007-10065-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well informed decisions and thereby improve the quality of health care services.
    [Show full text]
  • AATS Graham Foundation
    AATS GRAHAM FOUNDATION 1973-2013 40YEARS OF SUPPORTING DRIVING LEADERSHIP, LEARNING AND INNOVATION IN THE PURSUIT OF EXCELLENCE 2013 ANNUAL REPORT Excellence! 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40
    [Show full text]
  • Trade Mark Journal No
    Trade Mark Journal No. 001/2021 31 January, 2021 FEBRUARY 2021 Issue No. 002/2021 1 Trade Mark Journal No. 001/2021 31 January, 2021 CONTENTS General Information 3 Operating Hours 3 Submission of Application 3 Enquiries 3 Trademarks Legislation 4 Forms and Fees 4 INID Codes 5 First Schedule – Fees 7 Second Schedule – Forms 12 Third Schedule – Classification of Goods and Services 14 New Trade Mark Applications Filed 17 Change of Proprietor’s Name 79 Change of Proprietor’s Address 80 Change of Address for Service 83 Subsequent Proprietor Registered 84 Subsequent Proprietor and Address for Service Registered 85 Trade Mark Registered 86 Trade Mark Pending for Renewal (6 months before expiration date) 89 Trade Mark Unpaid Renewal Fee (6 months grace period after expiration date) 108 Trade Mark Renewed 144 Trade Mark Renewed and Change of Agent 145 Trade Mark Renewed and Restored 183 Trade Mark Removed Through Non-Payment of Renewal Fee 184 New Trade Mark Applications Filed Under The Madrid Protocol 185 Trade Mark Registered Filed Under the Madrid Protocol 298 Trade Mark Registered Filed Under the Madrid Protocol due to 18 Months Lapsed 304 Trade Mark Pending for Renewal Filed Under the Madrid Protocol 306 ******* 2 Trade Mark Journal No. 001/2021 31 January, 2021 General Information The Brunei Darussalam Intellectual Property Office (BruIPO) is an Office under the Attorney General’s Chamber and its premises with effect from the 1 April, 2019 and is situated at the following address: Brunei Darussalam Intellectual Property Office (BruIPO) Attorney General’s Chamber Knowledge Hub, Level 2, Anggerek Desa Technology Park Jalan Berakas BB3713, Brunei Darussalam Tel: +673 2380966 Opening Hours With effect from 1 January, 2020, the Brunei Intellectual Property Office (BruIPO) counter will operate as follows: Monday to Thursday : 8.00am to 12.00am 2.00pm to 3.00pm Saturday : 8.00am to 11.00am Friday and Sunday : CLOSED Submission of Applications 1.
    [Show full text]
  • Uncorrected Proof
    JrnlID 11097_ArtID 9157_Proof# 1 - 15/03/2010 Phenom Cogn Sci DOI 10.1007/s11097-010-9157-z 31 2 Sacred plants and visionary consciousness 4 José Luis Díaz 5 6 # Springer Science+Business Media B.V. 2010 7 8 Abstract Botanical preparations used by shamans in rituals for divination, 9 prophecy, and ecstasy contain widely different psychoactive compounds, which are 10 incorrectly classified under a single denomination such as “hallucinogens,” 11 “psychedelics,” or “entheogens.” Based on extensive ethnopharmacological search, 12 I proposed a psychopharmacological classification of magic plants in 1979. This 13 paper re-evaluates this taxonomy in the context of consciousness research. Several 14 groups of psychodysleptic magic plants are proposed: (1) hallucinogens—psilocybin 15 mushrooms, mescaline cacti, dimethyltryptamine snuffs, and the synthetic ergoline 16 lysergic acid diethylamide induce strong perceptual changes, affective intensifica- 17 Q1 tion, and cognitive enhancement. Their ethnobotanical uses include long lasting 18 divination rituals, prophecy, and sacramental practice. (2) Trance-inducers—ergoline 19 Convolvulaceae and South American Banisteriopsis produce quietness, abstraction, 20 lethargy, mild sensorial and cognitive changes, and salient visual imagery changes 21 used in trance rituals and specific divination practices. (3) Cognodysleptics— 22 marijuana (tetrahydrocannabinol) and other terpene-containing plants induce 23 Q2 changes in thought, imagination, and affective functions and are used in short-term 24 divination or oneiromancy. (4) Deliriants—tropane-containing Solanaceae, wild 25 tobacco, and Amanita muscaria (muscimol) induce a delirium characterized by dim 26 and clouded consciousness, stupor, confusion, disorientation, perception distortion, 27 difficultiesUNCORRECTED in recollection, anxiety, irritability, excitation, and PROOF behavioral disorgani- 28 zation employed in sorcery, purification, or exorcism rituals.
    [Show full text]